

## Technology Advisory Committee A Interests Register

**Topic: Tezepelumab for treating severe asthma [ID3910]**

**Publication Date: 20/04/2023**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Abdallah Al-Mohamma,	Committee member	Indirect financial	Professor Al-Mohammad has attended an advisory board with AstraZeneca for a different agent and different indication (Dapagliflozin the treatment of heart failure with preserved ejection fraction) in September 2022.	-	30/10/2022	-	It was agreed that his declaration would not prevent Professor Al-Mohammad from participating in discussions on this appraisal
Olivia Fulton, Patient	Patient expert	Direct non-financial	Olivia as she sits on the Astra Zeneca Patient Partnership Program but has not been involved in any work regarding this appraisal.	-	01/11/2022	-	It was agreed that her declaration would not prevent Olivia from providing expert advice to the committee.
David Jackson, Consultant Physician	Clinical Expert	Direct – Financial	David declared that as he works with all the main drug companies for educational events and he has received speaker fee's from many pharmaceutical companies which include AstraZeneca who are the part owner of Tezepelumab.	-	07/02/23	-	It was agreed that his declaration would not prevent David Jackson from providing expert advice to the committee

Dominic Pivonka	Committee Member	direct financial interest	His employer (AbbVie) has a medicine in a different therapy area (atopic dermatitis) which is a competitor to one of the comparators (dupilumab) in this appraisal.		27/01/2023 19/02/2023		It was agreed that his declaration would prevent Dominic Pivonka from participating in discussions on this appraisal.
-----------------	------------------	---------------------------	---	--	--------------------------	--	---